BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 16611636)

  • 21. Inhibition of the tumor-associated urokinase-type plasminogen activation system: effects of high-level synthesis of soluble urokinase receptor in ovarian and breast cancer cells in vitro and in vivo.
    Magdolen V; Krüger A; Sato S; Nagel J; Sperl S; Reuning U; Rettenberger P; Magdolen U; Schmitt M
    Recent Results Cancer Res; 2003; 162():43-63. PubMed ID: 12790320
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design of novel and selective inhibitors of urokinase-type plasminogen activator with improved pharmacokinetic properties for use as antimetastatic agents.
    Schweinitz A; Steinmetzer T; Banke IJ; Arlt MJ; Stürzebecher A; Schuster O; Geissler A; Giersiefen H; Zeslawska E; Jacob U; Krüger A; Stürzebecher J
    J Biol Chem; 2004 Aug; 279(32):33613-22. PubMed ID: 15150279
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity. EGF-receptor inhibition may prevent tumor cell dissemination.
    Festuccia C; Angelucci A; Gravina GL; Biordi L; Millimaggi D; Muzi P; Vicentini C; Bologna M
    Thromb Haemost; 2005 May; 93(5):964-75. PubMed ID: 15886816
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transforming Growth Factor-Beta and Urokinase Type Plasminogen Interplay in Cancer.
    Santibanez JF; Krstic J
    Curr Protein Pept Sci; 2018; 19(12):1155-1163. PubMed ID: 29086689
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The urokinase-type plasminogen activator system and its role in tumor progression].
    Kugaevskaya EV; Gureeva TA; Timoshenko OS; Solovyeva NI
    Biomed Khim; 2018 Nov; 64(6):472-486. PubMed ID: 30632975
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro.
    Stahl A; Mueller BM
    Cancer Res; 1994 Jun; 54(11):3066-71. PubMed ID: 8187097
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of tumor invasion by genomic down-regulation of matriptase through suppression of activation of receptor-bound pro-urokinase.
    Suzuki M; Kobayashi H; Kanayama N; Saga Y; Suzuki M; Lin CY; Dickson RB; Terao T
    J Biol Chem; 2004 Apr; 279(15):14899-908. PubMed ID: 14747469
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of urokinase by 4-substituted benzo[b]thiophene-2-carboxamidines: an important new class of selective synthetic urokinase inhibitor.
    Towle MJ; Lee A; Maduakor EC; Schwartz CE; Bridges AJ; Littlefield BA
    Cancer Res; 1993 Jun; 53(11):2553-9. PubMed ID: 8495419
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is there a role for urokinase-type plasminogen activator inhibitors as maintenance therapy in patients with ovarian cancer?
    van Dam PA; Coelho A; Rolfo C
    Eur J Surg Oncol; 2017 Feb; 43(2):252-257. PubMed ID: 27345498
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Macrophage colony-stimulating factor mediates invasion of ovarian cancer cells through urokinase.
    Chambers SK; Wang Y; Gertz RE; Kacinski BM
    Cancer Res; 1995 Apr; 55(7):1578-85. PubMed ID: 7882368
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor-associated urokinase-type plasminogen activator: biological and clinical significance.
    Schmitt M; Jänicke F; Moniwa N; Chucholowski N; Pache L; Graeff H
    Biol Chem Hoppe Seyler; 1992 Jul; 373(7):611-22. PubMed ID: 1515091
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro regulation of pericellular proteolysis in prostatic tumor cells treated with bombesin.
    Festuccia C; Guerra F; D'Ascenzo S; Giunciuglio D; Albini A; Bologna M
    Int J Cancer; 1998 Jan; 75(3):418-31. PubMed ID: 9455804
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TGF-β2 promotes RPE cell invasion into a collagen gel by mediating urokinase-type plasminogen activator (uPA) expression.
    Sugioka K; Kodama A; Okada K; Iwata M; Yoshida K; Kusaka S; Matsumoto C; Kaji H; Shimomura Y
    Exp Eye Res; 2013 Oct; 115():13-21. PubMed ID: 23810810
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Urokinase-type plasminogen activator (uPA) and its receptor (uPAR): development of antagonists of uPA/uPAR interaction and their effects in vitro and in vivo.
    Reuning U; Sperl S; Kopitz C; Kessler H; Krüger A; Schmitt M; Magdolen V
    Curr Pharm Des; 2003; 9(19):1529-43. PubMed ID: 12871066
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system.
    Yin S; Lockett J; Meng Y; Biliran H; Blouse GE; Li X; Reddy N; Zhao Z; Lin X; Anagli J; Cher ML; Sheng S
    Cancer Res; 2006 Apr; 66(8):4173-81. PubMed ID: 16618739
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Localization of urokinase to focal adhesions by human fibrosarcoma cells synthesizing recombinant vitronectin.
    Wilcox SA; Reho T; Higgins PJ; Tominna-Sebald E; McKeown-Longo PJ
    Biochem Cell Biol; 1996; 74(6):899-910. PubMed ID: 9164658
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasminogen-independent initiation of the pro-urokinase activation cascade in vivo. Activation of pro-urokinase by glandular kallikrein (mGK-6) in plasminogen-deficient mice.
    List K; Jensen ON; Bugge TH; Lund LR; Ploug M; Danø K; Behrendt N
    Biochemistry; 2000 Jan; 39(3):508-15. PubMed ID: 10642175
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer cells and effects of Helicobacter pylori.
    Iwamoto J; Mizokami Y; Takahashi K; Nakajima K; Ohtsubo T; Miura S; Narasaka T; Takeyama H; Omata T; Shimokobe K; Ito M; Takehara H; Matsuoka T
    Scand J Gastroenterol; 2005 Jul; 40(7):783-93. PubMed ID: 16109653
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Urokinase plasminogen activator and gelatinases are associated with membrane vesicles shed by human HT1080 fibrosarcoma cells.
    Ginestra A; Monea S; Seghezzi G; Dolo V; Nagase H; Mignatti P; Vittorelli ML
    J Biol Chem; 1997 Jul; 272(27):17216-22. PubMed ID: 9202045
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Urokinase Type Plasminogen Activator and the Molecular Mechanisms of its Regulation in Cancer.
    Santibanez JF
    Protein Pept Lett; 2017; 24(10):936-946. PubMed ID: 28820062
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.